Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients-Reference-Cited by-同舟云学术

Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients

Published:2020-07 Issue:7 Volume:26 Page:1280-1287
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Blocka Joanna,Hielscher Thomas,Goldschmidt Hartmut,Hillengass Jens

Funder

Bristol-Myers Squibb

Celgene

Amgen

Novartis

Janssen Pharmaceuticals

Sanofi

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference22 articles.

1. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma;McElwain;Lancet,1983

2. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma;Barlogie;Blood,1986

3. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma;Barlogie;Blood,1997

4. Double-intensive therapy in high-risk multiple myeloma;Harousseau;Blood,1992

5. Autotransplants in multiple myeloma: what have we learned?;Vesole;Blood,1996

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiomic nomogram for predicting high-risk cytogenetic status in multiple myeloma based on fat-suppressed T2-weighted magnetic resonance imaging;Journal of Bone Oncology;2024-08

2. Comparison of tandem and single autologous stem cell transplantation in multiple myeloma: a retrospective propensity score-matching study;2024-04-18

3. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?;Hematology/Oncology Clinics of North America;2023-12

4. Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support;Bone Marrow Transplantation;2022-10-19

5. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM);Leukemia & Lymphoma;2022-09-20